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Stroke is one of the most common pathologies worldwide, being the second leading cause of death 
and the third leading cause of disability in western countries (Feigin et al., 2017). It is a medical condition 
characterised by the death of brain cells as a result of the lack of oxygen and glucose due to the blood flow 
interruption to the brain by the rupture or the blockage of a brain blood vessel. The type of stroke caused by 
the rupture of an artery is called haemorrhagic stroke, whereas the one caused by the blockage of a vessel is 
known as ischemic stroke (Grysiewicz et al., 2008). 
Ischemic stroke is an acute cerebrovascular disease characterised by a cascade of pathological events 
including excitotoxicity, inflammation and cellular death. In fact, due to the lack of oxygen, brain cells lose 
their potential to produce energy and as ATP-dependent ion channels fail, the depolarisation of the cell 
membrane occurs. As a consequence, voltage-dependent Ca2+ channels are activated and Ca2+ enters to the 
cell, which triggers extra liberation of glutamate. Glutamate is an excitatory neurotransmitter and, therefore, 
its high concentration produces excitatory effects in both neural and glial cells. Subsequently, brain cells 
release Ca2+ dependent enzymes such as proteases and phospholipases, as well as reactive oxygen species 
(ROS), which are detrimental and contribute to the oedema formation, inflammation and cell death (Broughton 
et al., 2009; Martín et al., 2018; Belov-Kirdajova et al., 2020). Nevertheless, the region affected by ischemic 
stroke is not homogenously affected regarding metabolic and ionic changes and, therefore, two different 
regions can be distinguished within the infarcted area: the core and the penumbra. The core is characterised by 
permanent and lethally depolarisations of cells, while the penumbra is characterised by repetitive 
depolarisations known as peri-infarct depolarisations (Dirnagl et al., 1999). 
 
Figure 1. Simplified overview of the ischemic cascade.  Neurons depolarise due to the energy failure. Glutamate receptors are 
activated and Ca2+ enters to the cell. Similarly, Na+ also enters to the cell, while K+ is released. Diffusion of K+ and glutamate to the 
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extracellular compartment can trigger to peri-infarct polarisation. H2O enters to the cell because of osmotic gradients and leads to 
oedema. The intracellular Ca2+ activates different enzymes and produces oxidative stress (free radicals).  Free radicals trigger the 
formation of inflammatory mediators, which activate microglia and lead to the infiltration of blood cells. 
Ischemic stroke leads to an increase of the concentrations of purines, including adenosine 5’-
triphospate (ATP) and adenosine. These biomolecules act as extracellular signalling molecules through a wide 
variety of metabotropic P1, metabotropic P2Y and ionotropic P2X purinergic receptors (Burnstock, 2007). 
Particularly, P1 receptors are specific for adenosine and there are four different subtypes (A1, A2A, A2B, and 
A3), which are G protein-coupled receptors (GPCR) with seven transmembrane domains (Fredholm et al., 
2001). The expression of adenosine receptors (ARs) is widely distributed throughout the whole body including 
tissues such as heart, blood cells, kidney or brain, which implies many chemical effects (Borea et al., 2018). 
Therefore, adenosine has been related to many different physiological processes within the central nervous 
system (CNS), such as sleep homeostasis (Peng et al., 2020). However, the affinity of each receptor for 
adenosine is different and while A1 and A2A receptors show a high affinity, A2B and A3 receptors need higher 
concentrations of adenosine to be activated (Dunwiddie & Masino, 2001).  
For this reason, adenosine and its receptors might be promising imaging biomarkers for diagnosis and 
therapy evaluation of cerebrovascular diseases such as stroke. Particularly, the longitudinal expression of A1 
adenosine receptors (A1ARs) after cerebral ischemia has recently been studied using PET (Joya et al., 2021). 
This study observed that the [18F]CPFPX-PET signal increased at days 3 and 7 in relation to day 1 after stroke, 
concluding that it could be a promising imaging biomarker for ischemic stroke. Besides, A1ARs showed a 
neuroprotective role against cerebral ischemia trough the reduction of both reactive and proliferative 
microglia/macrophages.   
Conversely, the longitudinal expression of adenosine A2A receptors (A2ARs) after ischemic stroke has 
not been described yet and in vivo imaging techniques may be helpful to evaluate their in vivo expression. 
Non-invasive positron emission tomography (PET) is one of those in vivo imaging modalities used to diagnose 
neurological diseases such as stroke. It is based on the administration of labelled molecules with a positron 
emitting isotope called radiotracer which binds to enzymes and receptors, among others (Janssen et al., 2016). 
Progress in radiotracer chemistry has allowed for the development of new compounds to study ARs in vivo, 
either agonists or antagonists. One of those radiotracers is [11C]SCH442416, an antagonist compound with a 
high affinity for A2ARs (Ki=0.5), which is one of the most selective compounds when compared to other 
established radiotracers for A2ARs (Bauer & Ishiwata, 2009). In addition, it has been shown that 
[11C]SCH442416 can be used not only in rodents, but also in monkeys (Moresco et al., 2005) and humans 
(Ramlackansingh et al., 2011).  
As it is previously mentioned, in vivo imaging techniques have demonstrated that A1ARs are 
interesting imaging biomarkers of ischemia, since adenosine is a mediator in the ischemic response. However, 
the in vivo distribution of other ARs including A2ARs has been scarcely explored followed cerebral ischemia. 
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Hypothesis and objective 
We hypothesise that A2ARs have a key role in the ischemic response. For that reason, the main 
objective of this study was to evaluate the in vivo distribution of A2ARs before and after cerebral ischemia. To 
that end, rats were analysed with PET imaging and magnetic resonance imaging (MRI) during the following 
month after a preclinical model of ischemic stroke. 
Materials and methods 
The experimental protocol of cerebral ischemia in rats and the acquisition of both PET and MRI-T2W 
images were conducted at CIC biomaGUNE by the group of Abraham Martín. However, the analysis of the 
images obtained were conducted at Achucarro – Basque Center for Neuroscience by the author of this work.  
Cerebral ischemia 
Six adult male Sprague-Dawley rats (Janvier, France) were used for the experiment. Animals were 
anesthetised and induced to ischemic conditions by a transitory middle cerebral artery occlusion (MCAO) for 
90 minutes. The experimental protocol was conducted as previously reported by Joya and colleagues (Joya et 
al., 2021), following the ARRIVE guidelines and Directives of the European Union on animal ethics and 
welfare. In brief, animals were anesthetised with 2.5% isoflurane in 100% O2 and a 2.6 cm length of 4-0 
monofilament nylon suture was introduced into the right external carotid artery up to the level of the origin of 
the MCA was reached. During occlusion, animals were placed in their cages with free access to food and water. 
10 minutes before the end of 90-min occlusion, rats were re-anesthetised, the filament was removed to allow 
reperfusion and animals were kept in their cages. The study was approved by the animal ethics committee of 
CIC biomaGUNE. 
Experimental set up 
Rats were subjected to T2-weighted (T2W) MRI scans 24 h after reperfusion (i) to include animals 
showing cerebral ischemia in PET studies and (ii) to measure the volume of infarction. Rats were repeatedly 
subjected to PET scanning at day 0 (before MCAO) and at days 1, 3, 7, 14, 21 and 28 after cerebral ischemia 
to describe the distribution of A2ARs in the rat brain. 
Magnetic resonance imaging 
 Rats were anesthetised with isoflurane (2-2.5%) in a 30/70% mixture of O2/N2 to obtain MRI-T2W 
images.  Rats were put on a rat compatible MRI holder with normothermic conditions. Animal respiration rate 
and temperature were constantly assessed by a SAIIM1030 system (SA Instruments, NY, USA) while rats 
were in the MRI magnet. MRI images were acquired with a 7T horizontal bore Bruker Biospec USR 70/30 
MRI system (Bruker Biospin GmbH, Ettlingen, Germany),  interfaced to an AVANCE III console and with a 
BGA12-S imaging gradient insert (with a maximal gradient strength of 400 mT/m, switchable within 80µs). 
Measurements were performed with a 72 mm volumetric quadrature coil for excitation and a 20 mm rat brain 
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surface coil for reception. In order to focus on the regions of interest (ROIs), a scout scan was acquired at the 
beginning of the imaging session. MRI-T2W images were obtained with a Bruker’s RARE (Rapid Acquisition 
Relaxation Enhancement) sequence (Effective TE = 40 ms, TR 4400 ms, NA = 2; Matrix = 256 x 256 points; 
FOV = 25.6 x 25.6 mm; spatial resolution = 100 x 100 µm; 24 slices of 1 mm thickness covering the whole 
brain) to assess the volume of the infarcted area.  
Magnetic resonance imaging analysis 
 For image analysis, the open source software imageJ (National Institutes of Health, Maryland, USA) 
was used to define ROIs manually. Different regions were analysed including the total volume of ipsilateral 
and contralateral cerebral hemispheres, striatum and cortex. Moreover, the total volume of infarction was also 
evaluated, as well as the infarcted area in both the striatum and cortex. The total volume of the regions 
mentioned was quantified by summing the areas of slices based on hyperintense signals.  
Radiochemistry 
 The radiotracer used was [11C]SCH442416, a selective and brain-penetrant antagonist of A2ARs. The 
labelled molecule was generated in an IBA Cyclone 18/9 cyclotron and transferred to a TRACERlab FXC Pro 
synthesis module (GE Healthcare, Waukesha, WI, USA). The synthesis and quality control were conducted 
following previous protocols described by Moresco and colleagues (Moresco et al., 2005). 
Positron emission tomography scans and data acquisition 
 PET images were acquired using an Explore Vista PET-CT camera (GE Healthcare, Waukesha, WI, 
USA). Rats were anesthetised with 2-2.5% of isoflurance in 100% O2 and were placed into a PET acquisition 
system rat compatible holder. Rats were maintained in normothermia and their respiration rate and temperature 
were continuously assessed while the acquisition of images using a SAII M1030 system (SA Instruments, NY, 
USA). The radiotracer was administered intravenously by the tail vein using a 24-gauge catheter. Animals 
were scanned longitudinally before and during the following month after cerebral ischemia. The PET images 
obtained were acquired dynamically during 60 minutes using 36 frames (2 x 5s, 4 x 10s, 5 x 20s, 5 x 30s, 5 x 
60s, 5 x 120s, 5 x 180s, 5 x 300s).  
Positron emission tomography image analysis 
 An image analysis software called PMOD (version 3.5, PMOD Technologies Ltd, Zurich, Switzerland) 
was used to analyse PET signal. PET images were manually co-registered to MRI brain template to obtain 
spatial normalisation. Two different types of volumes of interest (VOIs) were defined: (1) A first set of VOIs 
was established to assess the whole brain [11C]SCH442416-PET signal. Those VOIs were manually drawn in 
both the ipsilateral and contralateral hemispheres on slices of MRI-T2W rat brain template from PMOD 
software. (2) Another set of VOIs was automatically defined in the striatum, hypothalamus, thalamus, cortex, 
hippocampus, and cerebellum by using the regions proposed by PMOD rat brain template, to assess the 
evolution of [11C]SCH442416-PET signal in both ipsilateral and contralateral hemispheres. The last four 
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frames were used to quantify radiotracer uptake during the last 15 minutes. Average values were calculated as 
percentage of injected dose per cubic centimetre (%ID/cc).  
Simplified Reference Tissue Model 
Simplified Reference Tissue Model (SRTM) is a kinetic model to quantify the kinetic parameters of a 
receptor in PET studies without the need to measure the arterial input function. Particularly, this model 
considers that there is a brain region without specific binding of the radiotracer, which is known as reference 
tissue. The model is based on the following assumptions: (1) the volume of distribution of unspecific binding 
is the same in both the reference and target tissues; (2) the pathology under study does not affect the reference 
tissue; (3) the kinetic parameters of the target tissue can be defined by a single compartment. The most 
important parameter of this model is the non-displaceable binding potential (BPnd), which refers to the ratio 
of precisely bound radiotracer to that of non-displaceable radiotracer in tissue at equilibrium. Other parameters 
such as R1 and k2a are also obtained by this model, defining the relative influx of radioactivity and the outflow 
rate constant from specific region to plasma (Lammertsma & Hume, 1996). The reference tissue used in this 
study was the cerebellum, because the expression of A2ARs is almost negligible in that region of the brain 
(Rosin et al., 1998). Hence, [11C]SCH442416 has been described as one of the most selective radiotracers for 
A2ARs based on the uptake ratio of striatum (receptor-rich region) to cerebellum (receptor-poor region) (Bauer 
& Ishiwata, 2009). 
 
Figure 2. Simplified Reference Tissue Model (SRTM). It is a model to assess the quantification of receptor kinetics without assessing 
the arterial input function. CREF= concentration in reference tissue; C1= concentration of free radiotracer; C2= concentration of 
specifically bound radiotracer; CT= sum of C1 and C2; K1= the rate constant to transfer from plasma to free region; k2= the rate constant 
to transfer from free to plasma; k3= the rate constant to transfer from free to bound region; k4= the rate constant to transfer from bound 
to free region; k2a= the overall rate constant to transfer from specific region to plasma; K1’= the rate constant to transfer from plasma 
to reference region; k2’= the rate constant to transfer from reference region to plasma; BPnd= the ratio of specific to non-displaceable 




 Statistical analyses were calculated using GraphPad Prism 8 (GraphPad Software LLC, San Diego, 
USA). The percentage of injected dose per cubic centimetre (%ID/cc), BPnd, influx (R1) and efflux (k2a) 
values in each region at different time point after ischemic stroke were averaged and compared using repeated 
measures ANOVA followed by Bonferrani multiple-comparison tests (post-hoc analysis). Similarly, the 
volumes of infarction within the hemisphere, cortex and striatum were also averaged and compared using 
repeated measures ANOVA followed by Bonferroni test for post-hoc analysis. Additionally, the correlation 
between infarcted ipsilateral hemisphere and midline displacement was performed with linear regression. The 
level of significance was set at P < 0.05. 
Results 
PET imaging evaluation of A2ARs in the healthy brain 
 The expression of A2ARs in healthy rat brains (control) was evaluated by PET. Time-activity curves 
(TACs) were quantified in different brain regions (striatum, hypothalamus, thalamus, cortex, hippocampus and 
cerebellum) to assess the concentration (%ID/cc) of [11C]SCH442416-PET signal uptake. The radiotracer 
showed a fast uptake in the different brain regions studied followed by a wash-up until reached steady state 
during the last 15 minutes. Likewise, the highest %ID/cc value was observed in the striatum in relation to the 
other brain regions (Fig. 3A-C). Despite this, cerebral regions such as hypothalamus, thalamus, cortex, 
hippocampus and cerebellum showed high [11C]SCH442416 uptake taking into account the low signal showed 
by PET images in these brain areas (Fig. 3B). For this reason, a more concise quantification of PET data was 
carried out with SRTM to discard the existence of non-specific binding by some of the rat brain regions.  
Kinetic parameters including BPnd, R1 and k2a were analysed with SRTM using the cerebellum as the 
reference tissue region. These results showed a significant increase of BPnd in the striatum in comparison to 
other rat brain regions (p < 0,001), which showed almost negligible values. As is it previously mentioned, 
BPnd refers to the ratio of bound to free radiotracer in a specific region in the brain. Therefore, these results 
supported the existence of non-specific [11C]SCH442416 binding in hypothalamus, thalamus, cortex and 
hippocampus. In contrast, no significant differences of the influx of the radiotracer to a specific region of the 
brain (R1) and the efflux of the radiotracer from a specific region to the blood compartment (k2a) were observed 





Figure 3. Expression of A2ARs in healthy rat brains. A: Time activity curve (%ID/cc) of [11C]SCH442416 in each rat brain region. 
B:  MRI-T2W, [11C]SCH442416-PET and co-registered MRI-PET images in healthy conditions (different axial planes in accordance 
to the regions studied). C: %ID/cc in different regions of the brain. D to F: Kinetic parameters of BPnd (D), R1 (E), and k2a (F) obtained 
in different regions using SRTM.  
Evaluation of brain infarction with MRI 
 MRI-T2W images of axial planes at day 1 are shown in the figure 4A. Hyperintense regions of the 
images demonstrated the vasogenic oedema formation due to the ischemic stroke.  
The extent of brain lesion was assessed at 24 hours after reperfusion showing a total volume of 
infarction of 282.78 ± 121.82 mm3 (mean ± sd). The most affected areas by the ischemic stroke were the cortex 
and striatum, since almost all the animals showed corticostrial infarctions. The volume of infarction in the 
cortex was 198.28 ± 98.67 mm3, whereas the striatum volume was 47.99 ± 8.68 mm3. As a result, more than 
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80% of infarction was distributed in the cortex and striatum and the rest was distributed in other brain regions 
such as hippocampus (data non shown) (Fig. 4B-C). 
The percentage of infarcted volume within each region (including the hemisphere, cortex and striatum) 
was also analysed. These results showed that in contrast to the percentage infarcted within the hemisphere 
(35%), most of the area of both the cortex (74%) (p < 0.001) and striatum was infarcted (69%) (p < 0.01) (Fig. 
4D). Moreover, linear regression was performed to study the relationship between the volume of infarcted 
ipsilateral hemisphere (%) and midline displacement (%). Indeed, these results showed a significant correlation 
between the volume of infarction and the midline displacement at 24 hours after cerebral ischemia (r2 = 0.9718, 
p < 0.001) (Fig. 4E). 
 
Figure 4. Description of the brain infarction. A: MRI-T2W images of axial planes at day 1 after cerebral ischemia. B: Total volume 
of infarction and volumes of infarction in the cortex and striatum (mm3) (**p < 0.01 striatum to total volume; #p < 0.05 striatum to 
cortex). C: Distribution of infarction in the cortex and striatum (%) (*p < 0.05 cortex to total volume and ***p < 0.001 striatum to total 
volume; #p < 0.05 striatum to cortex). D: Percentages of infarcted volume in the hemisphere, cortex and striatum when compared to 
total volume of each region (%) (**p < 0.01 striatum to hemisphere and ***p < 0.001 cortex to hemisphere). E: Lineal regression 
between infarcted ipsilateral hemisphere volume (%) and midline displacement (%) (r2 = 0.9718, p < 0.001).  
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Longitudinal PET imaging of A2ARs after cerebral ischemia in rats 
The longitudinal expression of A2ARs was evaluated with in vivo PET imaging using the radiotracer 
[11C]SCH442416 before (control) and at the following 28 days after cerebral ischemia. The intensity of the 
PET signal decreased in the ipsilateral striatum at day 1 after cerebral ischemia when compared to baseline 
levels (day 0) followed by an increase at day 3 after ischemia. Subsequently, PET signal decreased from days 
7 to 28 in relation to day 3 (Fig. 5). In contrast, the contralateral striatum did not show differences along 
different days after cerebral ischemia. 
 
Figure 5. Longitudinal images of MRI and [11C]SCH442416-PET before and after ischemia. MRI-T2W (A) and [11C]SCH442416-
PET (B) images of a representative rat brain before (day 0) and at days 1, 3, 7, 14, 21 and 28 after ischemic stroke. MRI-T2W (A) and 
co-registered [11C]SCH442416-PET- MRI-T2W (B) axial images show the ischemic lesion evolution over one month after stroke onset. 
PET imaging quantification of A2ARs after ischemic stroke in rats 
 The percentage of injected dose per cubic centimetre (%ID/cc), as well as kinetic parameters in specific 
brain regions were analysed, including both the striatum and cortex, in control (day 0) and during the following 
month after ischemic stroke in rats.  
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In the ipsilateral striatum, PET signal uptake (%ID/cc) showed the highest value at day 3 in comparison 
to control (day 0) and other time points after ischemia (Fig. 6A). In contrast, the peak value of BPnd was 
observed at day 0 followed by a decrease at day 1 after the ischemic stroke (p < 0.01). Subsequently, BPnd 
increased at day 3 and declined progressively from day 7 to 28 (p < 0.05, p < 0.01, p < 0.001) (Fig. 6C). 
Similarly, the highest %ID/cc value was observed at day 3 in relation to control (day 0) and other time points 
in the contralateral striatum (Fig. 6B). However, non-significant differences of BPnd were observed before 
and after ischemia (Fig. 6D). 
Values of the influx (R1) and efflux (k2a) at day 0 in the cerebral striatum showed that the concentration 
of radiotracer that entered to the region was higher than the concentration returned to the blood. No significant 
differences were observed for R1 values in both the ipsilateral and contralateral striatum and for values of 
efflux (k2a) in the ipsilateral striatum. However, values of efflux (k2a) showed a significant decrease at days 7 
and 21 in relation to control (day 0) (p < 0.05) (Fig. 6E to H). 
 
Figure 6. The kinetic parameters of A2ARs in the striatum. A, B: The percentage of injected dose per cubic centimetre (%ID/cc) in 
the ipsilateral (A) and the contralateral striatum (B) before (day 0) and the following month (days 1, 3, 7, 14, 21 and 28) of ischemic 
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stroke. C to H: Kinetic parameters of BPnd, R1 and k2a in the ipsilateral and the contralateral striatum obtained by SRTM (*p < 0.05, 
**p < 0.01 and ***p < 0.001 compared to day 0; &&&p < 0.001 compared to day 1; #p < 0.05, ##p < 0.01 and ###p < 0.001 compared to 
day 3).  
Similarly to the values observed in the striatum (Fig. 6A-B), PET signal uptake (%ID/cc) showed the 
highest value at day 3 in relation to control (day 0) and other time points after ischemia in both the ipsilateral 
and contralateral cortex (Fig. 7A-B). However, the cortex before (day 0) and at different days after ischemia 
showed negligible BPnd values. Despite this, there was a slight but significant increase at day 3 in relation to 
day 1 (p < 0.05), followed by a significant decrease at days 14, 21 and 28 (p < 0.05) in the ipsilateral cortex 
(Fig. 7C).  
Contrary to the values observed in the striatum (Fig. 6E to H), values of the radiotracer influx (R1) and 
efflux (k2a) at day 0 were similar in both the ipsilateral and contralateral cortex, which suggested that almost 
all the radiotracer concentration that entered to the cerebral cortex returned to the bloodstream (Fig. 7E to H).  
These results showed similar radiotracer influx values to the cortex before and after ischemia. 
However, the radiotracer efflux to the blood was impaired after ischemia in comparison to control cerebral 
cortex (day 0). In addition, BPnd for [11C]SCH44241 showed negligible values before and after ischemia. 
Therefore, our results suggested that %ID/cc values observed in both the ipsilateral and contralateral cerebral 




Figure 7. The kinetic parameters of A2ARs in the cortex. A, B: The percentage of injected dose per cubic centimetre (%ID/cc) in 
the ipsilateral (A) and the contralateral cortex (B) before (day 0) and the following month (days 1, 3, 7, 14, 21 and 28) of ischemic 
stroke. C to H: Kinetic parameters of BPnd, R1 and k2a in the ipsilateral and the contralateral cortex obtained by SRTM (*p < 0.05 and 
**p < 0.01 compared to day 0; &p < 0.05 and &&p < 0.01 compared to day 1; #p < 0.05, ##p < 0.01 and ###p < 0.001 compared to day 3; 
$p < 0.05 compared to day 7).  
Discussion 
 This study showed the in vivo distribution of A2ARs in healthy conditions and after ischemic stroke in 
rat brains by [11C]SCH442416-PET imaging. In the recent years, adenosine has been described to have a role 
in response to ischemic stroke (Ganesana & Benton, 2018). Therefore, it has been suggested to be an important 
pharmacological target in ischemic stroke due to its high concentrations after hypoxic conditions.  
 Our findings demonstrated that in vivo PET imaging was a useful technique for quantifying A2ARs in 
healthy and pathological conditions after ischemia. Particularly, our main results showed that A2ARs 
expression was mainly restricted to the striatum in healthy conditions (Fig. 3B), in contrast to A1ARs, which 
are widely distributed within the entire brain (Joya et al., 2021). Likewise, these results were consistent with 
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those previously described that showed a high density of A2ARs in the rat striatum (Rosin et al., 1998). In 
addition, other studies observed that specific radiotracers for A2ARs such as [11C]SCH442416 and 
[11C]Preladenant rapidly accumulated in the brain striatum of rats (Zhou et al., 2014), monkeys (Moresco et 
al., 2005; Zhou et al., 2017) and humans (Ramlackhansingh et al., 2011; Sakata et al., 2017). Overall, this 
study evidenced the usefulness of [11C]SCH442416 for studying the in vivo distribution of A2ARs by PET 
imaging. 
The SRTM kinetic model was used to quantify the kinetics of [11C]SCH442416 distribution in both 
rat striatum and cortex, since those are the most affected areas by model of preclinical stroke used in this study 
(MCAO) (Fluri et al., 2015). In the healthy striatum (day 0), the influx (R1) of the radiotracer was higher than 
its efflux (k2a) from the target tissue to the bloodstream, which suggested that the radiotracer remained in the 
striatum. These findings were supported by the increase of BPnd values in the striatum, evidencing the 
radiotracer binding to A2ARs. In contrast, healthy rat brain cortex displayed high influx (R1) and efflux (k2a) 
radiotracer values together with negligible BPnd values. Overall, these results showed a higher A2ARs 
concentration in the striatum in relation to cerebral cortex in healthy conditions (Fig. 3D-F). 
At 1 day after ischemia, [11C]SCH442416-PET uptake (%ID/cc) decreased in the ipsilateral striatum, 
due to the neuronal loss after hypoxic conditions. However, a slight recovery of the signal was observed at day 
3 followed by a sharp decline from day 7 to 28 (Fig. 6A). These results were confirmed by SRTM that showed 
a BPnd increase at day 3 in relation to day 1 followed by a progressive decline from day 7 to 28. Additionally, 
the influx (R1) and the efflux (k2a) radiotracer values showed non-significant differences along the month 
following ischemia in both the ipsilateral and contralateral striatum (Fig. 6E to H). Altogether, these findings 
suggested that the increase of [11C]SCH442416 BPnd observed in the ipsilateral striatum at day 3 after ischemia 
could be related to a higher expression of A2ARs. 
Within the cerebral cortex, [11C]SCH442416-PET uptake (%ID/cc) increased significantly at day 3 
after ischemia in relation to previous days followed by a sharp decrease later on (Fig. 7A-B). Nevertheless, the 
values obtained by SRTM showed that BPnd barely changed and was negligible before (day 0) and after 
ischemic stroke (Fig. 7C-D). Furthermore, the influx (R1) was maintained at similar values before and after 
ischemia. In contrast, the efflux (k2a) of the radiotracer was characterised by a sharp decline after ischemia in 
relation to day 0 in both the ipsilateral and contralateral cortex (Fig. 7E to H). Taken together, these results 
suggested that %ID/cc values observed in the cerebral cortex can be the result of non-specific binding of 
[11C]SCH442416. Despite these findings, PET results should be validated by immunohistochemistry of A2ARs 
in both the healthy and ischemic brain.  
Finally, this study showed that use of kinetic models such as SRTM can provide a more concise 
quantification of in vivo A2ARs distribution. Indeed, SRTM has been described as an accurate model to analyse 
the kinetics of a radiotracer when mapping A2ARs using the cerebellum as the reference tissue (Zhou et al., 
2017). However, SRTM assumes that the volume of the radiotracer is equally distributed in both the reference 
tissue and tissue of interest. As the blood brain barrier (BBB) is usually disrupted after ischemic stroke, the 
values obtained by SRTM might be influenced. As a result, SRTM would not be an accurate model to study 
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the brain kinetics of a radiotracer following cerebral ischemia. Despite this, Martin and colleagues showed that 
the disruption of BBB did not affect the accuracy of SRTM for the evaluation of similar radiotracers to study 
brain receptors after cerebral ischemia in rats.  These authors showed similar [11C]raclopride distribution using 
both in vivo imaging and ex vivo autoradiography (Martin et al., 2013). Hence, our in vivo PET imaging data 
should be validated by using ex vivo autoradiography to discard BBB disruption effect on [11C]SCH442416  
uptake after stroke. 
Conclusions 
To our knowledge, this was the first study that analysed the expression of A2ARs by PET in both 
healthy and ischemic conditions. [11C]SCH442416-PET demonstrated that A2ARs were mainly expressed in 
the healthy rat striatum. Additionally, the present findings showed that the expression of A2ARs increased in 
the ipsilateral striatum at day 3 after ischemic stroke followed by a progressive decrease later on. Finally, this 
study confirmed that PET quantification of [11C]SCH442416 using SRTM provided a more accurate 
information compared to the uptake signal (%ID/cc). Overall, the present study evidenced that 
[11C]SCH442416-PET imaging was a useful technique for analysing the in vivo distribution of A2ARs in the 
rat brain. However, further research is needed to gain knowledge about the possible function of A2ARs after 
ischemia.  
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